Evidence map›Paper›PMID 39203950›Full record

ReviewVaccines2024

Building Quality Control for Molecular Assays in the Global Measles and Rubella Laboratory Network.

Bettina Bankamp, Raydel Anderson, Lijuan Hao, Elena Lopareva, Min-Hsin Chen, Gimin Kim, R Suzanne Beard, Yoshio Mori, Noriyuki Otsuki, Akihido Ryo and 1 more

Abstract readReview
In one paragraph

Review in Vaccines, 2024. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 2 papers.

0numbers the graph read from it
0cells of the map it votes in
2citing papers in PubMed
–field-weighted citation impact
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

2 citing papers in PubMed.

  1. Review
  2. Review
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

11 authors.

Bettina BankampCenters for Disease Control and Prevention, 1600 Clifton Road N.E., Atlanta, GA 30329, USA.
Raydel AndersonCenters for Disease Control and Prevention, 1600 Clifton Road N.E., Atlanta, GA 30329, USA.ORCID 0000-0002-1334-3462
Lijuan HaoCenters for Disease Control and Prevention, 1600 Clifton Road N.E., Atlanta, GA 30329, USA.ORCID 0000-0002-4284-0855
Elena LoparevaCenters for Disease Control and Prevention, 1600 Clifton Road N.E., Atlanta, GA 30329, USA.
Min-Hsin ChenCenters for Disease Control and Prevention, 1600 Clifton Road N.E., Atlanta, GA 30329, USA.ORCID 0000-0002-8047-3961
Gimin KimCenters for Disease Control and Prevention, 1600 Clifton Road N.E., Atlanta, GA 30329, USA.
R Suzanne BeardCenters for Disease Control and Prevention, 1600 Clifton Road N.E., Atlanta, GA 30329, USA.
Yoshio MoriDepartment of Virology III, National Institute of Infectious Diseases, Tokyo 208-0011, Japan.
Noriyuki OtsukiDepartment of Virology III, National Institute of Infectious Diseases, Tokyo 208-0011, Japan.
Akihido RyoDepartment of Virology III, National Institute of Infectious Diseases, Tokyo 208-0011, Japan.
Paul A RotaCenters for Disease Control and Prevention, 1600 Clifton Road N.E., Atlanta, GA 30329, USA.

Funding

No grant is acknowledged in the PubMed record.

6 · The paper itself

Abstract

More than 100 laboratories in the World Health Organization Global Measles and Rubella Laboratory Network (GMRLN) perform nucleic acid-based methods for case confirmation of measles or rubella infections and/or strain surveillance (genotyping). The quality of laboratory data is critical to ensure that diagnostic results and country reports to regional verification committees are based on accurate data. A molecular External Quality Assurance (mEQA) program was initiated by the US-CDC in 2014 to evaluate the performance of laboratories in the network. The inclusion of testing for measles and rubella viruses, with a focus on detection and genotyping, plus the diversity of assays and platforms employed required a flexible and comprehensive proficiency testing program. A stepwise introduction of new evaluation criteria gradually increased the stringency of the proficiency testing program, while giving laboratories time to implement the required changes. The mEQA program plays an important role in many processes in the GMRLN, including informing plans for the training of laboratory staff, access to reagents, and the submission of sequence data to global databases. The EQA program for Local Public Health Institutes in Japan is described as an example for national mEQA programs. As more laboratories initiate molecular testing, the mEQA will need to continue to expand and to adapt to the changing landscape for molecular testing.

Indexed as

external quality assessmentgenotypingmeaslesrubella

Identifiers

PMID39203950
PMCPMC11359200

What OpenQuestion holds

Textmetadata
LicenceCC BY
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.